Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Nuvation Bio Inc. (NYSE: NUVB)
NUVB Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
32.60%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
151.60%
NUVB Stock Analysis
NUVB
PE Ratio:
NUVB
PEG Ratio:
Not Available
NUVB
Forward EPS Growth (12 month):
0.00%
NUVB
PS Ratio:
11.5
NUVB
PSG Ratio:
0.3
NUVB
Forward Revenue Growth (12 month):
42.60%
NUVB Articles
No data was found